LYMPHOMA, LARGE B-CELL, DIFFUSE

This program gives people with large B-cell lymphoma access to a CAR T-cell therapy called lisocabtagene maraleucel (liso-cel) that didn't pass all quality checks. It's only for patients who were already prescribed liso-cel as part of their regular care. Participants receive chem…

This study tests a new treatment called JNJ-90014496 (prizlo-cel) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer …

This study tests whether a new drug, zilovertamab vedotin, combined with standard chemotherapy (R-CHP) works better than another approved drug combo (polatuzumab vedotin + R-CHP) for people with a specific type of fast-growing blood cancer called GCB diffuse large B-cell lymphoma…

This study tests whether adding two targeted drugs, glofitamab and polatuzumab, to standard chemotherapy (R-CHP) can improve outcomes for people with high-risk diffuse large B-cell lymphoma. About 41 adults with untreated disease will receive the combination. The main goal is to …

This study tests a new type of PET scan that targets a protein called CD70, which is found on some cancer cells. The goal is to see if this scan can better detect kidney cancer, lymphoma, and nasopharyngeal cancer compared to standard scans. About 300 adults with known or suspect…